Delayed graft function (DGF) affects 25-30% of kidney transplant recipients, requiring dialysis in the first week post-surgery. Current immunosuppressive therapies don't address the underlying cell death mechanism—necroptosis—that drives graft injury. No FDA-approved therapy specifically prevents DGF.
Our researchers developed PGB-1, a novel peptidomimetic that specifically inhibits the PPP1R3G/PP1γ protein interaction—an upstream regulator of necroptosis. Unlike existing RIPK1 inhibitors, this targeted approach reduces cell death in kidney proximal tubular cells while minimizing off-target effects.